Trial of Pegcetacoplan in C3 Glomerulopathy and Immune-Complex MPGN

Fádi Fakhouri; Andrew S. Bomback; Gema Ariceta; Yahsou Delmas; Bradley P. Dixon; Daniel P. Gale; Larry A. Greenbaum; Seung Hyeok Han; Nicole M. Isbel; Moglie Le Quintrec; Christoph Licht; Antonio Mastrangelo; Masashi Mizuno; Maria Izabel Neves de Holanda; Matthew C. Pickering; Giuseppe Remuzzi; Nicole C. A. J. van de Kar; Marina Vivarelli; Patrick D. Walker; Dean Wallace; Daniel Zecher; Cedric Francois; Pascal Deschatelets; Li Li; Zhongshen Wang; Lydia Abad‐Franch; Nils Kinnman; Luis López Lázaro; Johan Szamosi; Carla Nester

doi:10.1056/nejmoa2501510

Related publications

Article2022

POS-048 PHASE 3, RANDOMIZED, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PEGCETACOPLAN IN TREATMENT OF C3G OR IC-MPGN

Giuseppe Remuzzi, Bradley P. Dixon, Fádi Fakhouri, Matthew C. Pickering, Terry Cook, D. Kavanagh, Patrick D. Walker, Christoph Licht, Gerald B. Appel, Marina Vivarelli, Zhuojing Zhang, L. Li, Hetal S. Kocinsky

Article2024

#1467 Pegcetacoplan for post-transplant recurrent C3 glomerulopathy or immune complex membranoproliferative glomerulonephritis in NOBLE: 12-week evolution

Fádi Fakhouri, Andrew S. Bomback, David Kavanagh, Giuseppe Remuzzi, Gere Sunder‐Plassmann, John Kanellis, Erica Daina, Patrick D. Walker, Zhongshen Wang, Zurish Ahmad

Article2025

VALIANT: Randomized, multicenter, double-blind, placebo-controlled, phase 3 trial of pegcetacoplan for patients with native or post-transplant recurrent C3G or primary (idiopathic) IC-MPGN

Carla Nester, Andrew S. Bomback, Gema Ariceta, Yahsou Delmas, Bradley P. Dixon, Daniel P. Gale, Larry A. Greenbaum, Seung Hyeok Han, Nicole M. Isbel, Christoph Licht, Antonio Mastrangelo, Masashi Mizuno, Maria Izabel Neves de Holanda, Matthew C. Pickering, Giuseppe Remuzzi, Nicole C. A. J. van de Kar, Marina Vivarelli, Patrick D. Walker, Dean Wallace, Daniel Zecher,

Article2025

#3265 Pegcetacoplan treatment effect in patients with nephrotic range proteinuria: results from the VALIANT Phase 3 study in patients with C3G or primary (idiopathic) IC-MPGN

Marina Vivarelli, Andrew S. Bomback, Gema Ariceta, Antonio Mastrangelo, Carla Nester, Giuseppe Remuzzi, Nicole C. A. J. van de Kar, Zhongshen Wang, Johan Szamosi, Dima Decker, Lenny Gallardo, Fádi Fakhouri

Article2025

#288 Pegcetacoplan demonstrates clinically significant responses in C3G and primary (idiopathic) IC-MPGN Patients with or without concomitant immunosuppression in VALIANT

David Kavanagh, Andrew S. Bomback, Gema Ariceta, Antonio Mastrangelo, Carla Nester, Giuseppe Remuzzi, Marina Vivarelli, Zhongshen Wang, Johan Szamosi, Dima Decker, Lenny Gallardo, Fádi Fakhouri

Trial of Pegcetacoplan in C3 Glomerulopathy and Immune-Complex MPGN

Abstract

Discussion(0)

Related publications

POS-048 PHASE 3, RANDOMIZED, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PEGCETACOPLAN IN TREATMENT OF C3G OR IC-MPGN

#1467 Pegcetacoplan for post-transplant recurrent C3 glomerulopathy or immune complex membranoproliferative glomerulonephritis in NOBLE: 12-week evolution

VALIANT: Randomized, multicenter, double-blind, placebo-controlled, phase 3 trial of pegcetacoplan for patients with native or post-transplant recurrent C3G or primary (idiopathic) IC-MPGN

#3265 Pegcetacoplan treatment effect in patients with nephrotic range proteinuria: results from the VALIANT Phase 3 study in patients with C3G or primary (idiopathic) IC-MPGN

#288 Pegcetacoplan demonstrates clinically significant responses in C3G and primary (idiopathic) IC-MPGN Patients with or without concomitant immunosuppression in VALIANT